Antiseptiske midler

Hibiwash

Hibiwash® er et antimikrobielt middel til preoperativ kirurgisk hånddesinfeksjon, antiseptisk håndvask på avdelingen og preoperativ og postoperativ hud-desinfeksjon for pasienter som gjennomgår elektiv kirurgi.

Produkt: REF {{ store.currentProductVariant?.productId }}
  • {{ feature }}
  • Sertifisert av ISCC
  • FSC-sertifisert papir
  1. Hvordan produktet fungerer

  2. Both Surgical site infections ( SSIs) and Healthcare acquired infections (HCAIs ) demand a coordinated approach pre-and post-surgery by healthcare professionals and their patients. Hibiwash® is your trusted partner in helping prevent infections, promote skin’s integrity and save time before performing surgical procedures. It contains 4% Chlorhexidine Gluconate for a wide range of antimicrobial activity and has been used for many decades in hospitals. Regular use of Hibiwash® can help reduce the chance of 11 in 100 patients contracting an SSI up to 30 days after surgery. It has also been shown to significantly decrease the risk of hospital-associated Staphylococcus aureus infections by up to 60% when used in combination with nasal antisepsis. Hibiwash® is not absorbed into the skin but binds to it to form a protective layer that removes and kills microorganisms and continues to do so for a long period of time after application. Unlike povidone iodine, Hibiwash® is not inactivated by bodily fluids. Hibiwash® has been reformulated to be a more sustainable product, using fewer raw materials and less energy in its production. The removal of colour, fragrance and traces of soya oil makes it less likely to create skin irritation or an allergic reaction and has the potential of an increased compliance. It also contains emollients and it is gentle on the skin even with frequent use.

    1. 01
    2. 02
    3. 03
    4. 04
    5. 05
    6. 06
    7. 07
    1. Garibaldi RA. Journal of Hospital Infection 1988; 11: 5-9
    2. Menon, V. Chapter 22 Sixth Edition 2021; Pages 477-506
    3. Jarral O et all 2011
    4. Byrne DJ et al. Journal of Hospital Infection 1990; 15:183-187
    5. Sheikh W. Current Therapeutic Research 1986;40(6): 1096-1102
    6. Faoagali et al. American Journal of Infection Control 2 1995
    7. Case DE., Chlorhexidine: Attempt to detect percutaneous absorption in man, Proceedings of the 9th International Congress of Chemotherapy, J.D. Williams & A.M. Geddes ED., 1976;3 (Chemotherapy): 367-374.
    8. Mölnlycke Health Care. Internal Report REPR0495. Data on file
    9. Tanner J et al. A fresh look at perioperative body washing. Journal of Infection Prevention. 2012; (13) 11 - 15.
    10. Molnlycke Internal Report REPR0781 (patch test study)
    11. Molnlycke Internal Report REPR1037
    12. Molnlycke Internal Report REPR1130
    13. SmPC
    14. Mölnlycke Health Care. Data on file.
    15. Gillespie B.M. 2021. Worldwide incidence of surgical site infections in general surgical patients: A systematic review and meta-analysis of 488,594 patients. International Journal of Surgery, 95, p.106136.
    16. Bode LGM et al. Preventing Surgical Site Infections in Nasal Carriers of Staphylococcus aureus. The New England Journal of Medicine 2010; 362(1): 9-17.
  3. Emballasjenivå Mengde GTIN-kode
    {{ row.packagingLevel }} {{ row.quantity }} {{ row.gtinCode }}

    {{ item.key }}: {{ item.value }}

Velg land

Få innsikt, lær mer om produktene våre, få kundestøtte og mye mer.

Norway

No markets

Finn ledige stillinger, våre finansrapporter og mer Mölnlycke konsern.

Mölnlycke corporate

Er du helsepersonell?

Denne nettsiden inneholder informasjon som kun er ment for helsepersonell. Ved å velge ‘Ja, jeg er’ bekrefter du at du er helsepersonell.at is only intended for healthcare professionals. By selecting ‘Yes, I am’ you confirm that you are a healthcare professional.

Nei, jeg er ikke helsepersonell